期刊文献+

HIV-1 p24 DNA和P24蛋白联合免疫小鼠的效果 被引量:2

Immunological efficiency induced by HIV-1 p24 DNA combined with P24 protein
原文传递
导出
摘要 DNA疫苗能够诱导机体产生特异的细胞免疫和体液免疫反应,在肿瘤和感染性疾病的疫苗开发中显示出巨大的潜能。以HIV-1核心蛋白P24为抗原基因,构建pVAX1-p24 DNA,经Western blotting和动物活体成像检测证明,pVAX1 DNA携带的外源基因可以在293T细胞和小鼠肌肉组织有效表达。采用不同的免疫策略免疫BALB/c小鼠(DNA/DNA,DNA/Protein),实验结果表明:pVAX1-p24单独免疫BALB/c小鼠,可诱导明显的体液免疫及细胞免疫反应;pVAX1-p24与P24蛋白联合免疫诱导的体液免疫反应高于pVAX1-p24单独免疫,所获得的抗体滴度是单独免疫的7.3~8.0倍,但细胞免疫反应则不及单独免疫组。研究结果表明采取不同的免疫策略可以诱导产生不同的免疫反应,根据具体情况调整免疫策略将获得更好的免疫效果。这些研究为艾滋病疫苗的研发提供了实验依据。 New strategies to improve vaccine efficacy against human immunodeficiency virus type 1(HIV-1) are still required.DNA vaccines,exhibiting potential advantages over conventional vaccines for their simplicity and versatility,can induce specific humoral and cellular immune responses.We developed a recombinant pVAX1 DNA vector carrying p24 gene of HIV-1.The results showed that pVAX1 mediated gene possessed the ability of effective expression in both transfected 293T cells and BALB/c mice.And pVAX1-p24 DNA prime and boost immunization can induce significant P24-specific humoral immune responses and cellular immune responses in BALB/c mice.Furthermore,immunization with pVAX1-p24 DNA prime and protein boost induced 7.3 to 8.0-fold greater p24-specific humoral responses than pVAX1-p24 DNA prime and boost,while the cellular immune responses induced by combined immunization was lower.The results suggested that pVAX1-p24 DNA and P24 protein vaccine is a promising HIV-1 vaccine,and the selections of the immunization strategies are important for the immunization results.774 ISSN1000-3061 CN11-1998/Q Chin J Biotech May 25,2011 Vol.27 No.5
出处 《生物工程学报》 CAS CSCD 北大核心 2011年第5期773-780,共8页 Chinese Journal of Biotechnology
基金 广东省引进创新科研团队基金资助~~
关键词 HIV-1 DNA疫苗 P24蛋白 免疫反应 HIV-1 DNA vaccine P24 protein immune response
  • 相关文献

参考文献25

  • 1Lu L, Jia M, Ma Y, et al. The changing face of HIV in China. Nature, 2008, 455(7213): 609-611.
  • 2Weiss RA. HIV and AIDS: looking ahead. Nat Med, 2003, 9(7): 887-891.
  • 3Greene WC. A history of AIDS: looking back to see ahead. Eur J Immunol, 2007, 37(Suppl 1): S94-S102.
  • 4Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature, 2008, 455(7213): 613-619.
  • 5Wyand MS, Manson KH, Garcia-Moll M, et al. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol, 1996, 70(6): 3724-3733.
  • 6Priddy FH, Brown D, Kublin J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis, 2008, 46(11): 1769-1781.
  • 7Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev, 2008, 9(10): 776-788.
  • 8Barouch DH, Yang ZY, Kong WP, et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol, 2005, 79(14): 8828-8834.
  • 9Marsac D, Puaux AL, cellular and humoral vectors encoding Riviere Y, et al. In vivo induction of immune responses by hybrid DNA simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice. Immunobiology, 2005, 210(5): 305-319.
  • 10Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis, 2006, 194(12): 1638-1649.

同被引文献29

  • 1章金刚,倪道明.生物制品的现状与展望[J].中国输血杂志,2006,19(5):349-351. 被引量:8
  • 2Triques K, Bourgeois A, Vidal N, et al. Near-full-length genome se- quencing of divergent African HIV type 1 subtype F viruses leads to the identification of a new HIV type I subtype designated K. AIDS Res Hum Retmvimses, 2000,16(2) : 139-151.
  • 3Patton JC, Coovadia All, Meyers TM, et al. Evaluation of the ultra- sensitive human immunedeficiency virus type 1 ( H1Y-1 ) p24 antigen assay performed on dried blood spots for diagnosis of HIV-1 infectionin infants. Clin Vaccine lmmunol, 2008, 15(2):388-391.
  • 4Wessman MJ, Theilgaard Z, Katzenstein TL. Determination of HIV status of infants born to HIV-infected mothers: a review of the diag- nostic methods with special focus on the applicability of p.24 antigen testing in developing countries. Scand J Infect Dis, 2012, 44(3): 209-215.
  • 5Kivuyo SL, Johannessen A, Trcseid M, et al. p24 antigen detection on dried blood spots is a feasible and reliable test for infant HIV infec- tion in rural Tanzania. Int J STD AIDS, 2011, 22(12): 719-721.
  • 6Cragin L, Pan F, Peng S, et al. Cost-effectiveness of a fourth- goneration combination itraramoassay for human imaamoddiciency virus (HIV) antibody and p24 antigen for the detection of HIV infec- tions in the United States. HIV Clin Trials, 2012, 13(1): 11-22.
  • 7Roodbari F, Sabahi F, Sarbolouki MN, et al. Inmmne responses against a new HIV-1 p24-gp41/pCAGC, S-IL-12 DNA vaccine in Balb/c mice. Iran J lmmunoi, 2012, 9(2):86-97.
  • 8Singer EJ, Syndulko K, Fahy-Chandon BN, et al. Cerebrospinal flu- id p24 antigen levels and intrathecal iramunoglobulin G synthesis are associated with cognitive disease severity in HIV-1. AIDS, 1994, 8(2): 197-204.
  • 9Moraes ML, Bonardi C, Mendonqa CR, et al. Cooperative effects in phospholipid monolayers induced by a peptide from H1V-1 capsid pro- tein. Colloids Surf B Biointerfaces, 2005, 41(1): 15-20.
  • 10Fadda L, Komer C, Kamar S, et al. HLA-Cw+ 0102-restricted HIV-1 p24 epitope variants can mod~ate the binding of the inhibitory KIR2DL2 receptor and primary NK cell function. PLoS Pathog, 2012, 8(7) :e1002805.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部